Overview

Liq-NOL Efficacy in Pediatric Patients With Down Syndrome

Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the effects of LiQ-NOL supplementation on language production using the Clinical Evaluation of Language Fundamentals test, language sampling using the mean length of utterance test, and speech articulation using the Goldman-Fristoe Test of Articulation.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Treatments:
Coenzyme Q10
Ubiquinone